Corporate Contact: Kevin MoranSenior Vice President, Chief Financial Officer and TreasurerVanda Pharmaceuticals Inc. 202-734-3400 pr@vandapharma.com Elizabeth Van Every Head of Corporate Affairs Vanda ...
Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2022 Vanda Pharmaceuticals Inc. Earnings Conference Call. I would now like to turn the call over to Kevin Moran, Vanda's Chief ...
Q2 2022 total revenues were $64.4 million Total revenues in the first six months of 2022 were $124.6 million Vanda provides update on pipeline advancements and upcoming milestones Net income was $2.6 ...
WASHINGTON, Feb. 17, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23, ...
WASHINGTON, July 27, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 on Wednesday, August 3, 2022, after the ...
WASHINGTON, June 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2022 Global Healthcare Conference in New ...
--Vanda Pharmaceuticals Inc. today announced financial and operational results for the fourth quarter and full year ended December 31, 2022. Total net product sales from HETLIOZ ® and Fanapt ® were ...
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2022 Vanda Pharmaceuticals Inc. Earnings Conference Call. I would now like to turn the call over to Kevin Moran, ...
Q4 2022 total revenues were $64.5 million Full year 2022 revenues were $254.4 million Vanda provides update on pipeline advancements and upcoming milestones WASHINGTON, Feb. 8, 2023 /PRNewswire/ -- ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results